Login to Your Account

Motif Bio shares rise as iclaprim passes first phase III test in ABSSSI

By Cormac Sheridan
Staff Writer

Tuesday, April 18, 2017

DUBLIN – Motif Bio plc is on course for an NDA filing next year for iclaprim, following a positive readout from the first of two phase III trials in patients with ABSSSI, in which it demonstrated noninferiority to vancomycin.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription